Ser349
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser349  -  CCR5 (human)

Site Information
stGEQEIsVGL____   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448724

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 10 ) , electrophoretic mobility shift ( 10 ) , flow cytometry ( 5 , 6 , 9 ) , mass spectrometry ( 1 , 3 , 4 ) , mutation of modification site ( 8 , 9 , 10 ) , phospho-antibody ( 2 , 5 , 7 ) , phosphoamino acid analysis ( 10 ) , western blotting ( 2 , 7 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 4 ) , lymphoma ( 9 ) , anaplastic large cell lymphoma ( 9 ) , pancreatic ductal adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:
'pancreatic, ductal'-pancreas ( 3 ) , 293 (epithelial) ( 7 ) , blood ( 6 ) , breast ( 1 ) , CCRF-CEM (T lymphocyte) ( 9 ) , CHO (fibroblast) ( 2 ) , COS (fibroblast) ( 10 ) , HOS (bone cell) ( 9 ) , lung ( 4 ) , monocyte ( 5 ) , RBL-2H3 (basophil) [CCR5 (human)] ( 8 ) , RBL-2H3 (basophil) ( 7 , 10 ) , T lymphocyte-blood ( 6 )

Upstream Regulation
Putative in vivo kinases:
GRK3 (human) ( 10 )
Treatments:
5P14-RANTES ( 2 ) , antibody ( 6 ) , AOP-RANTES ( 10 ) , bisindolylmaleimide ( 7 ) , CCL3 ( 9 ) , CCL5 ( 5 ) , LTA ( 5 ) , Maraviroc ( 6 ) , MIP-1beta ( 6 ) , phorbol_ester ( 7 ) , PSC-RANTES ( 2 ) , PTX ( 7 ) , RANTES ( 7 , 10 ) , Schering_X ( 6 )

Downstream Regulation
Effects of modification on CCR5:
activity, inhibited ( 8 ) , molecular association, regulation ( 8 ) , receptor desensitization, altered ( 10 ) , receptor internalization, altered ( 5 , 8 , 9 , 10 )
Induce interaction with:
ARRB1 (rat) ( 8 ) , ARRB2 (rat) ( 8 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Bönsch C, et al. (2015) Potent Anti-HIV Chemokine Analogs Direct Post-Endocytic Sorting of CCR5. PLoS One 10, e0125396
25923671   Curated Info

3

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

4

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

5

Fox JM, Letellier E, Oliphant CJ, Signoret N (2011) TLR2-dependent pathway of heterologous down-modulation for the CC chemokine receptors 1, 2, and 5 in human blood monocytes. Blood 117, 1851-60
21148810   Curated Info

6

Dahl ME, Berson A, Lora J, Fuentes M (2008) A novel CCR5-specific pharmacodynamic assay in whole blood using phosphoflow cytometry highlights different ligand-dependent responses but similar properties of antagonists in CD8+ and CD4+ T lymphocytes. J Pharmacol Exp Ther 327, 926-33
18753410   Curated Info

7

Pollok-Kopp B, Schwarze K, Baradari VK, Oppermann M (2003) Analysis of ligand-stimulated CC chemokine receptor 5 (CCR5) phosphorylation in intact cells using phosphosite-specific antibodies. J Biol Chem 278, 2190-8
12403770   Curated Info

8

Huttenrauch F, et al. (2002) Beta-arrestin binding to CC chemokine receptor 5 requires multiple C-terminal receptor phosphorylation sites and involves a conserved Asp-Arg-Tyr sequence motif. J Biol Chem 277, 30769-77
12065593   Curated Info

9

Brandt SM, et al. (2002) Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem 277, 17291-9
11782464   Curated Info

10

Oppermann M, Mack M, Proudfoot AE, Olbrich H (1999) Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. J Biol Chem 274, 8875-85
10085131   Curated Info